Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 229-237

  Kurrasch Orbaugh, Deborah M ^a   Watts, Val J ^a   Barker, Eric L ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROLAMFETAMINE; ERGOLINE DERIVATIVE; LIGAND; LISURIDE; LYSERGIDE; PHENETHYLAMINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PSILOCIN; QUIPAZINE; RECEPTOR RESERVE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 5 RECEPTOR; TRYPTAMINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

3T3 CELLS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ARACHIDONIC ACID; ENZYME ACTIVATION; ENZYME INHIBITORS; ERGOLINES; HYDROLYSIS; LIGANDS; MICE; PHENETHYLAMINES; PHENOXYBENZAMINE; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C; PHOSPHOLIPASES A; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; TRYPTAMINES;

EID: 0037215643     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042184     Document Type: Article

References (32)

1. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharrnacodyn 99:32-49.
2. Berg KA, Clarke WP, Chen Y, Ebersole BJ, McKay RD, and Maayani S (1994) 5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. Mol Pharmacol 45:826-836.
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
4. Berridge MJ (1983) Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem J 212:849-858.
5. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, and Nichols DE (2001) Enantio-specific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem 44:1003-1010.
6. Clapham DE and Neer EJ (1997) G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 37:167-203.
7. Clark AJ (1926) The antagonism of acetylcholine by atropine. J Physiol 61:547-556.
8. Colquhoun D (1998) Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
9. Downes GB and Gautam N (1999) The G protein subunit gene families. Genomics 62:544-552.
10. Furchgott RF (1955) The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183-265.
11. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001a) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
12. Ghanouni P, Steenhuis JJ, Farrens DL, and Kobilka BK (2001b) Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA 98:5997-6002.
13. Gilman AG (1987) G proteins: Transducers of receptor-generated signals. Annu Rev Biochem 56:615-649.
14. Hall RA, Premont RT, and Leikowitz RJ (1999) Heptahelical receptor signaling: Beyond the G protein paradigm. J Cell Biol 145:927-932.
15. Hoffman BB and Leikowitz RJ (1996) Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, and Gilman AG eds) pp 199-248, McGraw-Hill, New York.
16. Julius D, Huang KN, Livelli TJ, Axel R, and Jessell TM (1990) The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Natl Acad Sci USA 87:928-932.
17. Kanashiro CA and Khalil RA (1998) Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 25:974-985.
18. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
19. Leff P, Scaramellini C, Law C, and McKechnie K (1997) A three-state receptor model of agonist action. Trends Pharmacol Sci 18:355-362.
20. Mukherjee AB, Miele L, and Pattabiraman N (1994) Phospholipase A2 enzymes: Regulation and physiological role. Biochem Pharmacol 48:1-10.
21. Nickerson M (1956) Receptor occupancy and tissue response. Nature (Lond) 178: 697-698.
22. Offermanns S, Wieland T, Homann D, Sandmann J, Bombien E, Spicher K, Schultz G, and Jakobs KH (1994) Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. Mol Pharmacol 45:890-898.
23. Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, Roques BP, and Noble F (1999) The cholecystokinin B receptor is coupled to two effector pathways through pertussis toxin-sensitive and -insensitive G proteins. J Neurochem 73:281-288.
24. Powis G, Seewald MJ, Gratas C, Melder D, Riebow J, and Modest EJ (1992) Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res 52:2835-2840.
25. Robb S, Cheek TR, Hannan FL, Hall LM, Midgley JM, and Evans PD (1994) Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. EMBO (Eur Mol Biol Organ) J 13:1325-1330.
26. Sanders-Bush E, Burris KD, and Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928.
27. Seifert R, Wenzel-Seifert K, Gether U, and Kobilka BK (2001) Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297:1218-1226.
28. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11:379-393.
29. Sutherland CA and Amin D (1982) Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. Selective inhibition of diglyceride lipase by RHC 80267. J Biol Chem. 257:14006-14010.
30. Van Nueten JM, Janssen PA, Van Beek J, Xhonneux R, Verbeuren TJ, and Vanhoutte PM (1981) Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218:217-230.
31. Yang Q and Lanier SM (1999) Influence of G protein type on agonist efficacy. Mol Pharmacol 56:651-656.
32. Zifa E and Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401-458.